Real World Experience with Histological Confirmation of Clinical Response of SCC to Tirbanibulin

This retrospective case series evaluates the use of off-label tirbanibulin 1% ointment for treating biopsy-proven squamous cell carcinoma (SCC) and SCC in situ (SCCIS). The study involved 7 patients (5 females, 2 males) aged 59 to 78 years, all White with Fitzpatrick skin types II and III. The lesions, located on the cheek, temple, scalp, chest, and hand, ranged from 6 to 14 mm in size. Four patients had failed previous treatments (liquid nitrogen, imiquimod, fluorouracil, and photodynamic therapy). Tirbanibulin was applied nightly for 5 consecutive nights, following liquid nitrogen treatment to enhance penetration. Surgical excision with 4-mm margins was performed in most cases. Histological resolution, with no residual cancer cells, was achieved in 83% of excised lesions (5 of 6). One SCCIS resolved completely with tirbanibulin alone, avoiding surgery. Clinical improvement was observed in most cases, with one lesion fully resolving both clinically and histologically. Treatment courses ranged from 1 to 2, with a mean of 1.2 courses. Local skin reactions were mild to moderate, resolving by day 14. No recurrence was noted after 13 to 16 months, highlighting tirbanibulin’s potential as an effective adjunctive therapy for SCC and SCCIS.

Click here for a link to the original publication.

Elevate-Derm Alliance Editorial Committee